-1.69%

Gold vs US Dollar

Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Get Started

GSK Gsk Plc

1,488.50

11.00 (0.74%)

28 Mar 2025 - Closed

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Gsk Plc	LSE:GSK	London	Ordinary Share	GB00BN7SWP63	ORD 31 1/4P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	11.00	0.74%	1,488.50	1,486.00	1,486.50	1,491.00	1,476.50	1,478.00	5,748,076	16:35:14

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
Pharmaceutical Preparations	31.38B	2.58B	0.6211	23.93	61.26B

GSK, Alector Partner to Develop Antibodies for Neurodegenerative Diseases

02/07/2021 1:22pm

Dow Jones News

Gsk (LSE:GSK)
Historical Stock Chart

From Mar 2020 to Mar 2025

By Jaime Llinares Taboada

GlaxoSmithKline PLC said Friday that it has entered into a collaboration with Alector Inc. for the development and commercialization of two clinical stage monoclonal antibodies for neurodegenerative diseases.

The London-listed healthcare company said that Alector will receive $700 million in upfront payments and might receive an additional $1.5 billion in clinical development, regulatory and commercial launch-related milestone payments.

GSK said enrolment is currently underway for a Phase 3 trial for the AL001 antibodies, while AL101 is in Phase 1a clinical trial.

Both companies have agreed to co-commercialize and share profits in the U.S. GSK will retain exclusive commercialization rights outside the U.S.

Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT

(END) Dow Jones Newswires

July 02, 2021 08:08 ET (12:08 GMT)